Therapies and Diagnostics for Uterine Cancer

Report Code: HLC142A

Publish Date: Sep 2013

Publisher: BCC Publishing

Category: Health Maintenance

Customize This Report

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for uterine cancer treatments and diagnostics reached $17.4 billion in 2012. This market is expected to grow to nearly $17.8 billion in 2013 and then to nearly $21.6 billion in 2018, a compound annual growth rate (CAGR) of 3.9% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the global market for diagnostics and therapies for uterine cancer
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • A breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy
  • Discussion of uterine cancer biology
  • Delineation of drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic
  • Evaluation of the patent landscape
  • Comprehensive profiles of key companies.

SCOPE OF THE STUDY

The scope of this study is diagnostic test and therapeutic markets for uterine cancers. Screening tests are included as discussion only, as new studies have reflected that Pap smears, CT scans and ultrasound could be used as screening aids for uterine cancer. The exact usage for these tests for uterine cancer is still under research; therefore, sales numbers and revenue forecasts from this segment are not included in the final market summary. The focus of this report is on diagnostic tests and therapeutics for uterine cancer, including surgery and diagnostic methods (e.g., hysteroscopy and endometrial biopsy) that are currently in use. The report also includes discussions on the current technologies, new technologies, incidence, market projections and market share, along with the latest trends and new developments.

ABOUT THE AUTHOR

Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Therapies and Diagnostics for Uterine Cancer169 $2,500 Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3$250Free
Chapter- 3: OVERVIEW20$296Free
Chapter- 4: UTERINE CANCER: BIOLOGY12$178Free
Chapter- 5: UTERINE CANCER DIAGNOSIS AND SCREENING8$118Free
Chapter- 6: UTERINE CANCER TREATMENT STRATEGIES18$266Free
Chapter- 7: UTERINE CANCER INCIDENCE20$296Free
Chapter- 8: GLOBAL MARKET FOR UTERINE CANCER TREATMENTS AND DIAGNOSTICS30$444Free
Chapter- 9: TREATMENT MARKET40$592Free
Chapter- 10: PATENT LANDSCAPE3$44Free
Chapter- 11: SELECTED COMPANY PROFILES8$118Free
Chapter- 12: BIBLIOGRAPHY3$44Free

Recent Reports

Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

Published - Aug 2024 | Publisher - BCC Publishing | Code - HLC176E

The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.

Routine Health Screening Market

Published - Jul 2024 | Publisher - BCC Publishing | Code - HLC299A

The global market for routine health screening is expected to grow from $59.7 billion in 2024 and is projected to reach $82.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.8% during the forecast period of 2024 to 2029.

Elder Care Services and Assistive Devices: Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - HLC062E

The global market for elder care services and assistive devices is expected to grow from $868.2 billion in 2024 and is projected to reach $1.1 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 5.8% during the forecast period of 2024 to 2029.

Direct-to-Consumer Testing Industry: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC269B

The global market for direct-to-consumer (DTC) testing is estimated to increase from $1.6 billion in 2023 to reach $3.2 billion by 2029, at a compound annual growth rate (CAGR) of 12.5% from 2024 through 2029.

Health and Medical Insurance Providers: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC212B

The global market for health and medical insurance providers is expected to grow from $2.2 trillion in 2023 to $3.4 trillion by the end of 2028, at a compound annual growth rate (CAGR) of 8.9% during the forecast period of 2023 to 2028.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Therapies and Diagnostics for Uterine Cancer
Customize Report